Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Sabin-strain inactivated poliomyelitis vaccine (sIPV) is a trivalent biologic vaccine developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS). It is the world's first inactivated polio vaccine produced using attenuated Sabin strains (Types I, II, and III) rather than the traditional wild-type Salk strains. The vaccine is manufactured by growing the Sabin strains on Vero cells, followed by purification and formalin inactivation. It is administered via intramuscular injection and is indicated for the active prevention of poliomyelitis. By utilizing attenuated strains for production, sIPV significantly reduces the biosafety risks associated with manufacturing compared to traditional Salk-IPV, supporting global efforts to eradicate polio and facilitate the transition away from oral polio vaccines (OPV).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sabin-strain inactivated poliomyelitis vaccine (IMBCAMS).